Novotech Partners with Kyungpook National University Hospital to Strengthen Clinical Trial Capabilities in South Korea
18.3.2025 13:05:00 CET | Business Wire | Press release
Novotech, a global leading full-service clinical Contract Research Organization (CRO), and Acrostar, a provider of Site Management Organization (SMO) services have entered into a strategic partnership by signing a Memorandum of Understanding (MOU) with Kyungpook National University Hospital (KNUH). The partnership will support clinical trials across KNUH’s prestigious institutions including the Advanced Clinical Trials Center, the KNUH main campus, and the Chilgok KNUH in South Korea.
This collaboration is a key milestone for the advanced clinical trials in South Korea, strategically aligning with the amendments to the Advanced Regenerative Bio Act. This agreement builds upon the recent inauguration of KNUH’s Advanced Clinical Trials Center opened in November last year, marking its first official partnership post-amendment of the Bio Act.
The amendments to the Advanced Regenerative Bio Act expanded the scope of advanced regenerative medicine, allowing the use of investigational therapies in clinical trials and expanding the number of authorized regenerative medicine institutions. Previously limited to severe, rare, and incurable diseases, regenerative medicine applications will now extend to a broader range of conditions, including general diseases.
Patients outside of clinical trials will also gain access to regenerative medicine services, while the range of applicable technologies—including cell and gene therapies (CGT) and tissue engineering—has significantly expanded.
Under the previous framework, CGTs required formal drug approval for clinical application. With these regulatory changes, CGTs in clinical trials can now be utilized upon review committee approval, streamlining access to innovative therapies.
The partnership creates a comprehensive framework across KNUH’s network with early-stage clinical trials primarily conducted at the Advanced Clinical Trials Center, while late-stage trials will be managed with the KNUH’s hospital system itself.
Speaking at the ceremony, Prof. Hyungran Yoon, Director of the Advanced Clinical Trials Center, spoke about the benefits of the collaboration, “The Advanced Clinical Trials Center will oversee trials for all diseases treated at KNUH, strengthening our role as a leader in clinical research and regenerative medicine. The partnership agreement with Novotech will expand their capacity to offer innovative treatment opportunities both domestically and internationally.”
Dr. Yooni Kim, Managing Director, Asia-Pacific at Novotech, highlighted the strategic advantages. “This partnership combines Novotech’s global expertise with KNUH’s specialized capabilities to offer cutting-edge treatment solution and streamlined trial operations. By leveraging this synergy, we aim to boost South Korea’s position on the global stage in regenerative medicine and enhance clinical trial excellence worldwide.”
This partnership also marks a significant milestone for Acrostar, Novotech’s SMO services provider. Daniel Kim, Director of Acrostar Asia-Pacific, shared his excitement about the partnership, “This is Acrostar’s first partnership in South Korea. Through this collaboration, we will actively support the site and ensure the smooth progress of clinical trials from a site management perspective.”
This strategic partnership means a shared commitment to advancing clinical research in South Korea and contributing to the global development of regenerative medicine and advanced clinical trials.
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech and small to mid-size companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Fierce CRO 2024 Excellence Award in Clinical Trial Management and Global Operations, Frost & Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena 2024 Excellence Awards in Business Expansion, Innovation and Marketing, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317570511/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant Group Open-Sources Ling-3.0-flash-Fin for Real-World Financial Workflows9.9.2026 10:36:00 CEST | Press release
Ant Group today announced the open-sourcing of Ling-3.0-flash-Fin at the 2026 Inclusion·Conference on the Bund. Grounded in actual business needs as an open model for real-world financial workflows, this release continues Ant Group's exploration of bringing AI into practical scenarios, focusing on delivering utility and high efficiency for complex tasks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908565055/en/ Solving Real-World Challenges Through Efficiency Financial work depends on trustworthy sources, consistent definitions, accurate calculations and auditable outputs. AI in this sector must go beyond simple question-and-answer interactions to navigate dynamic information, complex accounting standards, and stringent compliance requirements. Ling-3.0-flash-Fin was co-developed with leading financial institutions and industry experts to embed professional expertise directly into task definition, data systems, and eva
1NCE adds Data Benchmarking, AI Capabilities and ISO certification9.9.2026 10:00:00 CEST | Press release
1NCE Insights now offers access to benchmarks from 30,000+ global deployments across 17 industries, enabling customers to compare their solutions to real-world peers. Launch of 1NCE AI, a unified API gateway providing access to leading AI models with centralized vendor management. ISO/IEC 27001:2022 certified infrastructure, reflecting 1NCE's commitment to data security. 1NCE announced a new upgrade of 1NCE Insights and the launch of 1NCE AI. Both expand 1NCE's foundational platform services, giving customers greater intelligence and control over connected device data. The new 1NCE Insights upgrade gives customers access to aggregated benchmark data from 30,000+ deployments. They can compare network usage patterns, battery performance, hardware choices and traffic optimization against real-world peers, enabling faster product development. 1NCE AI provides access to leading AI models through a unified API gateway, eliminating vendor fragmentation. The service is Germany-hosted and fully
HSCALE Secures Landmark Strategic Deal With Major US Cloud Provider for Hyperscale Data Centre Campus in Spain9.9.2026 09:00:00 CEST | Press release
The deal represents over US$1 billion in contract value which underpins the expansion and development of one of Spain's largest data centres currently under construction Major long-term agreement with a leading global cloud platform provider. First Ready-for-Service date in 2027. Project represents approximately US$1 billion of capex investment, strengthening and further cementing Spain's position in Europe's AI and cloud economy HSCALE, the pan-European hyperscale data centre platform, announced today a major strategic deal with a significant global cloud provider to deliver large-scale, high-performance digital infrastructure in a strategic metropolitan area within the Iberian Peninsula. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909242953/en/ HSCALE's CCO Paul Berry-Selwood The agreement is a defining milestone for HSCALE and anchors the development of a next-generation campus designed for the demanding requirement
Fighting Fire with Fire: Mobileum and Apate Shut Down Scam Operations From the Inside Out9.9.2026 09:00:00 CEST | Press release
AI-powered conversational agents help CSPs go beyond call and message blocking, disrupting fraudsters before they reach real customers. Mobileum Inc. (“Mobileum”), a leading global provider of analytics and network solutions, and Apate.ai (“Apate”) have announced a partnership that equips communications service providers (CSPs) with advanced AI-powered fraud prevention capabilities designed to detect, disrupt, and investigate scam call operations. According to the Global Anti-Scam Alliance, scammers stole an estimated $442 billion in 2025, with phone calls, text messages and emails being the top three communication channels used by scammers. Through the integration of Mobileum’s Active Intelligence Platform with Apate's conversational AI agents, CSPs can now move beyond traditional call blocking and take a more proactive role in disrupting scam activity. Rather than simply preventing suspicious calls, messages and other communications from reaching customers, the solution engages fraud
FinXP Partners with Thredd to Strengthen Multi-Region Card Issuing Capabilities9.9.2026 09:00:00 CEST | Press release
Mastercard principal member FinXP is combining its issuing capabilities with Thredd’s AI-first issuer-processing platform to support scalable debit card programmes across Europe and future growth markets FinXP, a European payment infrastructure provider, has partnered with Thredd, the AI-first issuer processing platform, to strengthen FinXP’s card issuing capabilities and support the next phase of its embedded finance offering. The partnership with Thredd will enable FinXP to enhance its debit card programmes with a modern issuer-processing stack, supporting tokenisation, provisioning, risk and fraud prevention, card controls, and automated back-office operations. FinXP will retain control of its own ledger and programme strategy, while Thredd will provide the programme infrastructure needed to support secure, scalable and flexible card issuing across multiple regions. FinXP has been issuing cards for five years and already supports businesses with accounts, payments, collections, payo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom